SCHEDULE 13G: Balyasny Asset Management Discloses 6.22% Stake in Avalo

Balyasny Asset Management and its affiliates have reported a 6.22% beneficial ownership stake in Avalo Therapeutics Inc., totaling 817,436 shares.

Summary

• Balyasny Asset Management L.P. and its related entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) have filed a Schedule 13G.
• The filing discloses beneficial ownership of 817,436 shares of Avalo Therapeutics Inc. common stock.
• This represents approximately 6.22% of Avalo Therapeutics Inc.'s outstanding Class A common stock.
• The ownership percentage is based on 13,152,356 shares of Class A common stock outstanding as of August 6, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P., is the direct holder of 250,000 warrants exercisable into shares and has the right to receive dividends or proceeds from the sale of the reported securities.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. The acquisition of a significant stake by an institutional investor can be interpreted as a neutral to slightly positive signal by the market.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Avalo Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector, where institutional investors often take positions based on pipeline potential, market trends, or strategic developments. A 6.22% stake by a prominent asset manager like Balyasny could signal confidence in the company's long-term prospects or a strategic investment in the sector.

Related Party Transactions

• Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P., is the direct holder of 250,000 warrants exercisable into shares and has the right to receive dividends or proceeds from the sale of the reported securities.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a 6.22% stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a substantial shareholder may influence strategic decisions or communication with the investment community.

Key Dates

Keywords

Avalo Therapeutics, Balyasny Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Equity Stake, Biotechnology